OncoMatch/Clinical Trials/NCT05899465
Perioperative Treatment With Tranexamic Acid in Melanoma
Is NCT05899465 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Tranexamic acid and Saline for melanoma.
Treatment: Tranexamic acid · Saline — Surgery is a key element in the treatment of melanoma, and naturally linked with an inflammatory response and recruitment of innate immune cells. Although surgery has a favorable intent, surgery-induced inflammation, neutrophils in particular, may accelerate growth of local and systemic micrometastases. Thus, improving cancer surgery and modulating the wound microenvironment in ways that benefit the patients is crucial. Repurposing already approved drugs in a cancer setting has gained increasing interest in recent years. Interestingly, tranexamic acid was recently suggested as an anti-cancer drug, capable of reducing tumor growth in experimental animal models and reducing the viability of different melanoma cell lines. As a novel approach, sponsor and investigators will conduct a Randomised Clinical Trial, using perioperative treatment with Tranexamic Acid, aiming to prevent the early relapses for patients with melanoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Melanoma
Disease stage
Required: Stage ≥T2B
pathological stage/tumor grade ≥T2b, defined as either: Breslow thickness >1.0-2.0 mm with presence of ulceration or Breslow thickness >2.0 mm regardless of ulceration status.
Prior therapy
Cannot have received:
With a prior history of invasive melanoma
Cannot have received: (tranexamic acid)
Current use of tranexamic acid
Lab requirements
Kidney function
egfr >50
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify